Cancer, Liver Dysfunction
Conditions
Brief summary
The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe hepatic impairment relative to patients with normal hepatic function, as categorized by the United States National Cancer Institute organ dysfunction working group \[NCI-ODWG\] criteria for hepatic dysfunction.
Detailed description
Hepatic impairment is a common co-morbidity in cancer patients, particularly in those with extensive liver metastases. Decreased drug clearance as a result of impaired liver function may lead to increased systemic exposure and possibly greater toxicity. As many chemotherapeutic agents are metabolized by the liver, treatment options tend to be limited in patients with severe hepatic impairment, even in the presence of good performance status and adequate other organ function. Cisplatin is an active chemotherapeutic agent with broad spectrum activity that can safely be administered in severe hepatic impairment. Cisplatin has been combined safely with full dose oral TS-1 with good efficacy in a spectrum of solid tumors in patients with adequate renal and hepatic function. The purpose of this study is to formally characterize the pharmacokinetics (PK), safety, and tolerability of TS-1 in combination with cisplatin in adult patients with advanced solid tumors who have mild, moderate or severe hepatic impairment relative to patients with normal hepatic function, as categorized by the United States National Cancer Institute organ dysfunction working group \[NCI-ODWG\] criteria for hepatic dysfunction.
Interventions
DRUGTS-1 combined with cisplatin
Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
Sponsors
National University Hospital, Singapore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
Patients must fulfill ALL the following inclusion criteria * Age 18 years. * Histologic or cytologic diagnosis of carcinoma, that is either refractory to standard therapy or has no available therapies. * Measurable disease using the RECIST v1.1 criteria * ECOG performance 0 or 1. * Estimated life expectancy of at least 12 weeks. * Adequate bone marrow and renal function as follows: Bone marrow: Absolute neutrophil count (ANC) 1.5 x 109/L Platelets 100 x 109/L Renal: calculated creatinine clearance \>60ml/minute Total bilirubin and AST/ALT as described in Table 1 * Able to swallow pills * Signed informed consent from patient or legal representative * Patients with reproductive potential must use an approved contraceptive method if appropriate (e.g., intrauterine device, birth control pills, or barrier device) during and for three months after the study. * Females with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment.
Exclusion criteria
Patients will be excluded from the study for any of the following reasons: * Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy. * Treatment of a small molecule targeted agents ≤ 2 weeks prior to starting study treatment * Treatment within the last 30 days with any investigational drug. * Radiotherapy ≤4 weeks prior to starting study treatment or who have not recovered from radiotherapy-related toxicities. Limited field palliative radiotherapy ≤ 2 weeks prior to starting study treatment is allowed * Major surgery within 28 days of study drug administration. * History or presence of serious uncontrolled ventricular arrhythmias * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of TS-1 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) * Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not mandatory) * Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy. * Pregnancy. * Breast feeding. * Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator. * Poorly controlled diabetes mellitus. * Second primary malignancy that is clinically detectable at the time of consideration for study enrollment * Symptomatic brain metastasis. * History of significant neurological or mental disorder, including seizures or dementia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy evaluations: Disease status | Radiological evaluation of tumor status every 2 cycles of cisplatin and oral TS-1 from baseline until documented disease progression; assessed up to 12 months | Efficacy evaluations will be performed using the RECIST v1.1 criteria Measurable disease: Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of 10mm on CT scan Malignant lymph node: ≥15mm in short axis on CT scan Non-measurable disease: All other lesions, including small lesions (longest diameter \<10mm or pathological lymph nodes with \>10 to \<15mm short axis) as well as truly non-measurable lesions |
| Efficacy Evaluation: Timing | 5 years | The duration of tumor response is measured from the date of enrollment until the first date of documented disease progression or death due to any cause, whichever occurs first. |
Countries
Singapore
Outcome results
None listed